市場調査レポート

商品コード

1804277

POCT (ポイントオブケア検査) の世界市場：製品・検査タイプ・適応症・技術・サンプルタイプ・購入形態・エンドユーザー・流通チャネル・地域別 - 市場規模・産業力学・機会分析・予測 (2025～2033年)

Global Point-of-Care Testing Market: By product, Test Type, Indication, Technology, Sample Type, Mode of Purchase, End Users, Distribution Channel, Region-Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2025-2033

出版日: 2025年07月16日
発行: Astute Analytica
ページ情報: 英文 260 Pages
納期: 即日から翌営業日

価格

PDF (Single User License)

USD 4,250 631,210円

レポートPDFを1名の方にご利用いただけるライセンスです。PDF内のテキスト等のコピー&ペースト、印刷はできません。

PDF & Excel (Multi User License)

USD 5,250 779,730円

レポートPDF・Excelを7名の方にご利用いただけるライセンスです。PDF・Excel内のテキスト等のコピー&ペーストは可能ですが、印刷はできません。

PDF, Excel & PPT (Corporate User License)

USD 6,400 950,528円

レポートPDF・Excel・PPTを企業内の全ての方にご利用いただけるライセンスです。PDF・Excel・PPT内のテキスト等のコピー&ペースト、及び印刷は可能です。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=148.52円

全表示
概要
目次

概要

サンプル依頼リストに入れる

世界のPOCT (ポイントオブケア検査)市場は、特に分散化したヘルスケア環境における迅速診断ソリューションに対する需要の高まりにより、大きな変革期を迎えています。市場規模は2024年の4,648万米ドルから、予測期間中は7.33％のCAGRで推移し、2033年には8,555万米ドルに達すると予測されています。糖尿病や心血管疾患といった慢性疾患の有病率の上昇に加え、感染症の迅速な診断ニーズが市場拡大を後押ししています。

医療機関の多くは、従来の中央ラボ型の検査から、より迅速な意思決定と高いアクセス性を実現するPOCTへと移行しつつあります。この変化は導入率にも表れており、POCTを導入している医療施設は2020年の4万2,000件から2024年には6万8,000件に増加しました。こうした進化により、リアルタイムでの患者データ分析が可能となり、特に糖尿病管理、心疾患イベントのモニタリング、緊急時の治療において重要な役割を果たしています。

市場セグメンテーション

製品別では、繰り返し利用される性質と診断に不可欠であることから、検査キットおよび消耗品の部門が市場をリードし、シェアは65.55％に達しています。この中には、グルコース検査ストリップ (128億米ドル)、ラテラルフローカートリッジ (84億米ドル)、凝固モニタリングキットなどが含まれます。これらは日常検査から緊急検査まで幅広く使用されており、継続的な収益源となっています。また、製造技術の進歩によってコスト削減とアクセス拡大が進んでいます。

検査タイプ別では、免疫学的POCTが市場を支配しており、世界の収益の41.41％以上を占めています。これらの検査は、HIV、肝炎、心疾患などの迅速な現場診断を可能にします。使いやすさとコスト効率の高さ (1テストあたり2.85米ドル程度) から、都市部と医療サービスが不足している地域の両方で迅速診断の基盤となっています。

適応症別では、感染症が主要用途であり、市場の31.30％以上を占めています。呼吸器感染症、HIV、肝炎といった疾患の高い発生率に加え、大規模検査を求める公衆衛生上の要請が、この分野の優位性を強固にしています。2024年には、世界で28億件以上の呼吸器検査と14億件の胃腸系病原体検査が実施されました。

地域別インサイト

北米

北米は2024年の収益が186億4,882万米ドルを超える世界的リーダーであり、広範な保険適用と強固なヘルスケアインフラに支えられています。特に米国はトップ市場であり、23万8,000の医師オフィスにおいて年間18億件の検査を実施しています。主要な研究機関や政府機関による大規模投資が、継続的な技術進歩と市場浸透を確実なものにしています。

アジア太平洋

アジア太平洋は最も急成長している地域であり、CAGRは8.27％に達しています。中国、インド、日本、東南アジアなどの国々における医療の近代化は、大規模な政府資金によって後押しされています。例えば、インドのAyushman Bharat制度は5億人以上の国民にサービスを提供しており、大量のPOCT需要を生み出しています。さらに、現地製造や官民連携によって、地域の能力が一層強化されています。

欧州

欧州各国も、EUの入札、中央集権型の医療イニシアチブ、抗菌薬耐性検査の広範な導入を通じて取り組みを強化しています。ドイツ、フランス、英国といった国々は、国民皆保険制度やイノベーショングラントを通じて、POCTへのアクセス性を高めています。

当レポートでは、世界のPOCT (ポイントオブケア検査) の市場を調査し、場概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

The global Point-of-Care Testing (POCT) Market is undergoing a significant transformation, driven by the rising demand for rapid diagnostic solutions, especially in decentralized healthcare environments. Valued at US$ 46.48 million in 2024, the market is forecast to reach US$ 85.55 million by 2033, growing at a CAGR of 7.33% between 2025 and 2033. The accelerating prevalence of chronic illnesses such as diabetes and cardiovascular disorders, combined with the need for swift diagnosis of infectious diseases, is propelling market expansion.

A growing number of healthcare facilities are transitioning from centralized lab-based testing to POCT for faster decision-making and greater accessibility. The adoption rate reflects this shift, with 68,000 healthcare sites worldwide integrating POCT in 2024, compared to 42,000 in 2020. This evolution enables real-time patient data analysis, particularly critical in managing diabetes, monitoring cardiac events, and administering treatment during emergencies.

Noteworthy Market Developments

The year 2024 saw 67 new POCT devices cleared by the FDA, a testament to the market's innovation momentum. Several of these solutions are equipped with AI capabilities and integrated with Electronic Health Records (EHRs) to streamline clinical workflows. Multiplex assays capable of detecting multiple pathogens from a single sample are also revolutionizing diagnostics by reducing testing complexity and result turnaround time.

Concurrently, the at-home testing segment is expanding rapidly, supported by regulatory endorsements such as the FDA's clearance of an over-the-counter dual test for influenza and COVID-19 in early 2025. Companies are investing in developing portable PCR-based systems and mobile diagnostics suited for emergency and rural environments. The direct-to-consumer market alone is expected to grow from US$ 7.8 billion in 2025 to over US$ 11.8 billion by 2035.

Strategic partnerships, acquisitions, and technology funding have shaped a competitive environment where companies such as Roche, Abbott, and Danaher are not only consolidating their market position but also pioneering advanced diagnostics through AI, cloud connectivity, and miniaturized devices.

Core Growth Drivers

Chronic Disease Burden: Increasing global incidence of diabetes, cardiovascular disorders, and infectious diseases demanding continual monitoring.
Rapid Diagnostics Demand: Emergency and remote settings necessitate quicker turnaround times, fueling POCT adoption.
Technological Integration: AI, cloud computing, and smartphone compatibility are enhancing test accuracy and accessibility.
Regulatory Acceleration: Government incentives and expedited device approvals are encouraging market entry and innovation.
Decentralized Healthcare Models: Shifting care delivery to homes, pharmacies, and community health centers is creating sustained demand.

Emerging Technology Trends

AI in Diagnostics: Integration of machine learning to interpret results and guide clinical decisions is becoming a standard feature in new POCT devices.
Multiplex POCT Assays: Advanced tests that detect multiple biomarkers in one go are growing at a projected rate of 25%.
Smartphone Connectivity: The number of devices linked to smartphones is set to increase by 30%, facilitating remote care models.
Cloud-Based Reporting: The use of cloud platforms for real-time result sharing and storage is expected to grow by 35% over the next few years.
Miniaturized Platforms: Portable diagnostics, such as mobile CT and PCR devices, are making POCT viable even in ambulances and rural settings.

Barriers to Optimization

High Cost of Advanced Devices: AI-integrated and multiplex systems come with significant capital and operational expenses.
Training and Standardization Gaps: Ensuring accuracy in non-laboratory environments remains a challenge due to variability in user expertise.
Regulatory Complexity Across Regions: Diverse regulations for OTC vs. prescription-based testing can complicate global product rollouts.
Data Security: The rise in cloud-based diagnostics raises cybersecurity concerns related to patient data.

Market Segment Analysis

The Testing Kits & Consumables category leads the market with a 65.55% share, driven by their recurring nature and indispensable use in diagnostics. These include high-demand items like glucose test strips (US$ 12.8 billion), lateral flow cartridges (US$ 8.4 billion), and coagulation monitoring kits. Their role in routine and emergency testing ensures a continuous revenue stream, with advanced manufacturing helping reduce costs and widen accessibility.

From a test-type perspective, Immunological PoC Tests dominate the landscape, contributing over 41.41% of global revenue. These tests enable fast, point-of-use diagnosis of conditions like HIV, hepatitis, and cardiac diseases. Their ease of use and cost-effectiveness (as low as US$ 2.85/test) have made them the cornerstone of rapid diagnostics in both urban and underserved settings.

In terms of indication, Infectious Diseases remain the primary application, accounting for over 31.30% of the market. High incidence rates of conditions like respiratory infections, HIV, and hepatitis, combined with public health mandates for mass testing, reinforce this segment's leadership. More than 2.8 billion respiratory tests and 1.4 billion gastrointestinal pathogen tests were conducted globally in 2024.

Additionally, Prescription-Based Testing remains the dominant mode, holding a 53.25% share. These tests, such as HbA1c and metabolic panels, require physician oversight and are tightly integrated into insurance reimbursement and regulatory frameworks, ensuring quality and proper clinical guidance.

Market Segmentation

By Product

Devices & Instruments
Diagnostic Analyzers & Testing Devices
Blood Gas & Electrolyte Analyzers
Cardiac Biomarker Analyzers
Glucose Monitoring Devices
Coagulation Testing Analyzers
Urinalysis Analyzers
Routine Clinical Chemistry Analyzers
Others
Monitoring Devices
Blood Pressure Monitors
Thermometers
Pulse Oximeters
Others
Testing Kits & Consumables
Blood Gas & Electrolyte Test Kits
Cardiac Biomarker Test Kits
Routine Clinical Chemistry Test Kits
Hematology Test Kits Coagulation Testing Kits
Urinalysis Test Strips & Kits
Cholesterol Test Strips
Drugs Abuse Testing Kits
Pregnancy And Fertility Testing Kits
Others

By Test Type

Immunological PoC Tests
Nucleic Acid-Based PoC Tests
Biomarker-Based PoC Tests

By Indication

Infectious Diseases
HIV
COVID-19
Others
Oncology
Cardiovascular Diseases
Metabolic Disorders
Respiratory Diseases
Neurological Disorders
Gastrointestinal Disorders
Others

By Technology

Biosensor Technology
Microfluidic Lab-On-A-Chip Technology
Molecular Diagnostics
Immunoassays
Others

By Sample Type

Blood
Urine
Saliva
Others

By Mode Of Purchase

Prescription-based Testing
Over the Counter (OTC) Testing

By End User

Hospitals & Clinics
Diagnostic Centers
Homecare Settings
Research Laboratories
Others

By Distribution Channel

Direct Distribution
Retail Pharmacies
Online Pharmacies
Others

Geographic Insights

North America

North America stands as the global leader, with 2024 revenue exceeding US$ 18,648.82 million, supported by extensive insurance coverage and robust healthcare infrastructure. The U.S., in particular, is the top-performing country, conducting 1.8 billion annual tests across 238,000 physician offices. Massive investment from leading institutions and government bodies ensures continued technological advancement and market penetration.

Asia Pacific

Asia Pacific is the fastest-growing region with a CAGR of 8.27%. Healthcare modernization across countries such as China, India, Japan, and Southeast Asia is bolstered by massive government funding. For instance, India's Ayushman Bharat scheme serves over 500 million citizens, driving high-volume POCT demand. Local manufacturing and public-private partnerships further amplify regional capabilities.

Europe

European nations are also ramping up efforts through EU tenders, centralized healthcare initiatives, and widespread adoption of antimicrobial resistance testing. Countries like Germany, France, and the UK are enhancing POCT accessibility through universal health schemes and innovation grants.

By Region

North America
The U.S.
Canada
Mexico
Europe
Western Europe
The UK
Germany
France
Italy
Spain
Rest of Western Europe
Eastern Europe
Poland
Russia
Hungary
Rest of Eastern Europe
Asia Pacific
China
India
Japan
South Korea
Australia & New Zealand
ASEAN
Rest of Asia Pacific
Middle East
UAE
Saudi Arabia
Bahrain
Kuwait
Qatar
Rest of Middle East
Africa
Morocco
Egypt
Nigeria
South Africa
Rest of Africa
South America
Argentina
Brazil
Rest of South America

Leading Market Participants

Abbott Laboratories
F. Hoffmann-La Roche Ltd
Danaher Corporation
Becton, Dickinson and Company (BD)
bioMerieux SA
Bio-Rad Laboratories, Inc.
Other Prominent Players

Table of Content

Chapter 1. Research Framework

1.1. Research Objective
1.2. Type Overview
1.3. Market Segmentation

Chapter 2. Research Methodology

2.1. Qualitative Research
- 2.1.1. Primary & Secondary Sources
2.2. Quantitative Research
- 2.2.1. Primary & Secondary Sources
2.3. Breakdown of Primary Research Respondents, By Region
2.4. Assumption for the Study
2.5. Market Size Estimation
2.6. Data Triangulation

Chapter 3. Executive Summary: Global Point-of-Care Testing Market

Chapter 4. Global Point-of-Care Testing Market Overview

4.1. Industry Value Chain Analysis
- 4.1.1. Material Provider
- 4.1.2. Manufacturer
- 4.1.3. Distributor
- 4.1.4. End User
4.2. Industry Outlook
4.3. PESTLE Analysis
4.4. Porter's Five Forces Analysis
- 4.4.1. Bargaining Power of Suppliers
- 4.4.2. Bargaining Power of Buyers
- 4.4.3. Threat of Substitutes
- 4.4.4. Threat of New Entrants
- 4.4.5. Degree of Competition
4.5. Market Dynamics and Trends
- 4.5.1. Growth Drivers
- 4.5.2. Restraints
- 4.5.3. Opportunities
- 4.5.4. Key Trends
4.6. Market Growth and Outlook
- 4.6.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2033
- 4.6.2. Price Trend Analysis
4.7. Competition Dashboard
- 4.7.1. Market Concentration Rate
- 4.7.2. Company Market Share Analysis (Value %), 2024
- 4.7.3. Competitor Mapping & Benchmarking
4.8. Actionable Insights (Analyst's Recommendations)

Chapter 5. Global Point-of-Care Testing Market Analysis, By Product

5.1. Key Insights
5.2. Market Size and Forecast, 2020-2033 (US$ Mn)
- 5.2.1. Devices & Instruments
  - 5.2.1.1. Diagnostic Analyzers & Testing Devices
    - 5.2.1.1.1. Blood Gas & Electrolyte Analyzers
    - 5.2.1.1.2. Cardiac Biomarker Analyzers
    - 5.2.1.1.3. Glucose Monitoring Devices
    - 5.2.1.1.4. Coagulation Testing Analyzers
    - 5.2.1.1.5. Urinalysis Analyzers
    - 5.2.1.1.6. Routine Clinical Chemistry Analyzers
    - 5.2.1.1.7. Others
  - 5.2.1.2. Monitoring Devices
    - 5.2.1.2.1. Blood Pressure Monitors
    - 5.2.1.2.2. Thermometers
    - 5.2.1.2.3. Pulse Oximeters
    - 5.2.1.2.4. Others
- 5.2.2. Testing Kits & Consumables
  - 5.2.2.1. Blood Gas & Electrolyte Test Kits
  - 5.2.2.2. Cardiac Biomarker Test Kits
  - 5.2.2.3. Routine Clinical Chemistry Test Kits
  - 5.2.2.4. Hematology Test Kits Coagulation Testing Kits
  - 5.2.2.5. Urinalysis Test Strips & Kits
  - 5.2.2.6. Cholesterol Test Strips
  - 5.2.2.7. Drugs Abuse Testing Kits
  - 5.2.2.8. Pregnancy And Fertility Testing Kits
  - 5.2.2.9. Others

Chapter 6. Global Point-of-Care Testing Market Analysis, By Test Type

6.1. Key Insights
6.2. Market Size and Forecast, 2020-2033 (US$ Mn)
- 6.2.1. Immunological PoC Tests
- 6.2.2. Nucleic Acid-Based PoC Tests
- 6.2.3. Biomarker-Based PoC Tests

Chapter 7. Global Point-of-Care Testing Market Analysis, By Indication

7.1. Key Insights
7.2. Market Size and Forecast, 2020-2033 (US$ Mn)
- 7.2.1. Infectious Diseases
  - 7.2.1.1. HIV
  - 7.2.1.2. COVID-19
  - 7.2.1.3. Others
- 7.2.2. Oncology
- 7.2.3. Cardiovascular Diseases
- 7.2.4. Metabolic Disorders
- 7.2.5. Respiratory Diseases
- 7.2.6. Neurological Disorders
- 7.2.7. Gastrointestinal Disorders
- 7.2.8. Others

Chapter 8. Global Point-of-Care Testing Market Analysis, By Technology

8.1. Key Insights
8.2. Market Size and Forecast, 2020-2033 (US$ Mn)
- 8.2.1. Biosensor Technology
- 8.2.2. Microfluidic Lab-On-A-Chip Technology
- 8.2.3. Molecular Diagnostics
- 8.2.4. Immunoassays
- 8.2.5. Others

Chapter 9. Global Point-of-Care Testing Market Analysis, By Sample Type

9.1. Key Insights
9.2. Market Size and Forecast, 2020-2033 (US$ Mn)
- 9.2.1. Blood
- 9.2.2. Urine
- 9.2.3. Saliva
- 9.2.4. Others

Chapter 10. Global Point-of-Care Testing Market Analysis, By Mode of Purchase

10.1. Key Insights
10.2. Market Size and Forecast, 2020-2033 (US$ Mn)
- 10.2.1. Prescription-based Testing
- 10.2.2. Over the Counter (OTC) Testing

Chapter 11. Global Point-of-Care Testing Market Analysis, By End User

11.1. Key Insights
11.2. Market Size and Forecast, 2020-2033 (US$ Mn)

Chapter 12. Global Point-of-Care Testing Market Analysis, By Distribution Channel

12.1. Key Insights
12.2. Market Size and Forecast, 2020-2033 (US$ Mn)

Chapter 13. Global Point-of-Care Testing Market Analysis, By Region

13.1. Key Insights
13.2. Market Size and Forecast, 2020-2033 (US$ Mn)
- 13.2.1. North America
  - 13.2.1.1. The U.S.
  - 13.2.1.2. Canada
  - 13.2.1.3. Mexico
- 13.2.2. Europe
  - 13.2.2.1. Western Europe
    - 13.2.2.1.1. The UK
    - 13.2.2.1.2. Germany
    - 13.2.2.1.3. France
    - 13.2.2.1.4. Italy
    - 13.2.2.1.5. Spain
    - 13.2.2.1.6. Rest of Western Europe
  - 13.2.2.2. Eastern Europe
    - 13.2.2.2.1. Poland
    - 13.2.2.2.2. Russia
    - 13.2.2.2.3. Rest of Eastern Europe
- 13.2.3. Asia Pacific
  - 13.2.3.1. China
  - 13.2.3.2. India
  - 13.2.3.3. Japan
  - 13.2.3.4. South Korea
  - 13.2.3.5. Australia & New Zealand
  - 13.2.3.6. ASEAN
  - 13.2.3.7. Rest of Asia Pacific
- 13.2.4. Middle East & Africa
  - 13.2.4.1. UAE
  - 13.2.4.2. Saudi Arabia
  - 13.2.4.3. South Africa
  - 13.2.4.4. Rest of MEA
- 13.2.5. South America
  - 13.2.5.1. Argentina
  - 13.2.5.2. Brazil
  - 13.2.5.3. Rest of South America

Chapter 14. North America Point-of-Care Testing Market Analysis

14.1. Key Insights
14.2. Market Size and Forecast, 2020-2033 (US$ Mn)
- 14.2.1. By Product
- 14.2.2. By Test Type
- 14.2.3. By Indication
- 14.2.4. By Technology
- 14.2.5. By Sample Type
- 14.2.6. By Mode of Purchase
- 14.2.7. By End User
- 14.2.8. By Distribution Channel
- 14.2.9. By Country

Chapter 15. Europe Point-of-Care Testing Market Analysis

15.1. Key Insights
15.2. Market Size and Forecast, 2020-2033 (US$ Mn)
- 15.2.1. By Product
- 15.2.2. By Test Type
- 15.2.3. By Indication
- 15.2.4. By Technology
- 15.2.5. By Sample Type
- 15.2.6. By Mode of Purchase
- 15.2.7. By End User
- 15.2.8. By Distribution Channel
- 15.2.9. By Country

Chapter 16. Asia Pacific Point-of-Care Testing Market Analysis

16.1. Key Insights
16.2. Market Size and Forecast, 2020-2033 (US$ Mn)
- 16.2.1. By Product
- 16.2.2. By Test Type
- 16.2.3. By Indication
- 16.2.4. By Technology
- 16.2.5. By Sample Type
- 16.2.6. By Mode of Purchase
- 16.2.7. By End User
- 16.2.8. By Distribution Channel
- 16.2.9. By Country

Chapter 17. Middle East & Africa Point-of-Care Testing Market Analysis

17.1. Key Insights
17.2. Market Size and Forecast, 2020-2033 (US$ Mn)
- 17.2.1. By Product
- 17.2.2. By Test Type
- 17.2.3. By Indication
- 17.2.4. By Technology
- 17.2.5. By Sample Type
- 17.2.6. By Mode of Purchase
- 17.2.7. By End User
- 17.2.8. By Distribution Channel
- 17.2.9. By Country

Chapter 18. South America Point-of-Care Testing Market Analysis

18.1. Key Insights
18.2. Market Size and Forecast, 2020-2033 (US$ Mn)
- 18.2.1. By Product
- 18.2.2. By Test Type
- 18.2.3. By Indication
- 18.2.4. By Technology
- 18.2.5. By Sample Type
- 18.2.6. By Mode of Purchase
- 18.2.7. By End User
- 18.2.8. By Distribution Channel
- 18.2.9. By Country

Chapter 19. Company Profile (Company Overview, Financial Matrix, Key Type landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

19.1. Abbott Laboratories
19.2. F. Hoffmann-La Roche Ltd
19.3. Danaher Corporation
19.4. Becton, Dickinson and Company (BD)
19.5. bioMerieux SA
19.6. Bio-Rad Laboratories, Inc.
19.7. Other Prominent Players

Chapter 20. Annexure

20.1. List of Secondary Sources
20.2. Key Country Markets - Marco Economic Outlook/Indicators

POCT (ポイントオブケア検査) の世界市場：製品・検査タイプ・適応症・技術・サンプルタイプ・購入形態・エンドユーザー・流通チャネル・地域別 - 市場規模・産業力学・機会分析・予測 (2025～2033年)

Global Point-of-Care Testing Market: By product, Test Type, Indication, Technology, Sample Type, Mode of Purchase, End Users, Distribution Channel, Region-Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2025-2033

目次

第1章 調査の枠組み

第2章 調査手法

第3章 エグゼクティブサマリー：世界のPOCT (ポイントオブケア検査) 市場

第4章 世界のPOCT (ポイントオブケア検査) 市場：概要

第5章 世界のPOCT (ポイントオブケア検査) 市場の分析：製品別

第6章 世界のPOCT (ポイントオブケア検査) 市場の分析：検査タイプ別

第7章 世界のPOCT (ポイントオブケア検査) 市場の分析：適応症別

第8章 世界のPOCT (ポイントオブケア検査) 市場の分析：技術別

第9章 世界のPOCT (ポイントオブケア検査) 市場の分析：サンプルタイプ別

第10章 世界のPOCT (ポイントオブケア検査) 市場の分析：購入形態別

第11章 世界のPOCT (ポイントオブケア検査) 市場の分析：エンドユーザー別

第12章 世界のPOCT (ポイントオブケア検査) 市場の分析：流通チャネル別

第13章 世界のPOCT (ポイントオブケア検査) 市場の分析：地域別

第14章 北米のPOCT (ポイントオブケア検査) 市場の分析

第15章 欧州のPOCT (ポイントオブケア検査) 市場の分析

第16章 アジア太平洋のPOCT (ポイントオブケア検査) 市場の分析

第17章 中東・アフリカのPOCT (ポイントオブケア検査) 市場の分析

第18章 南米のPOCT (ポイントオブケア検査) 市場の分析

第19章 企業プロファイル

第20章 付録

Noteworthy Market Developments

Leading Market Participants

Table of Content

Chapter 1. Research Framework

Chapter 2. Research Methodology

Chapter 3. Executive Summary: Global Point-of-Care Testing Market

Chapter 4. Global Point-of-Care Testing Market Overview

Chapter 5. Global Point-of-Care Testing Market Analysis, By Product

Chapter 6. Global Point-of-Care Testing Market Analysis, By Test Type

Chapter 7. Global Point-of-Care Testing Market Analysis, By Indication

Chapter 8. Global Point-of-Care Testing Market Analysis, By Technology

Chapter 9. Global Point-of-Care Testing Market Analysis, By Sample Type

Chapter 10. Global Point-of-Care Testing Market Analysis, By Mode of Purchase

Chapter 11. Global Point-of-Care Testing Market Analysis, By End User

Chapter 12. Global Point-of-Care Testing Market Analysis, By Distribution Channel

Chapter 13. Global Point-of-Care Testing Market Analysis, By Region

Chapter 14. North America Point-of-Care Testing Market Analysis

Chapter 15. Europe Point-of-Care Testing Market Analysis

Chapter 16. Asia Pacific Point-of-Care Testing Market Analysis

Chapter 17. Middle East & Africa Point-of-Care Testing Market Analysis

Chapter 18. South America Point-of-Care Testing Market Analysis

Chapter 19. Company Profile (Company Overview, Financial Matrix, Key Type landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

Chapter 20. Annexure

第1章調査の枠組み

第2章調査手法

第3章エグゼクティブサマリー：世界のPOCT (ポイントオブケア検査) 市場

第4章世界のPOCT (ポイントオブケア検査) 市場：概要

第5章世界のPOCT (ポイントオブケア検査) 市場の分析：製品別

第6章世界のPOCT (ポイントオブケア検査) 市場の分析：検査タイプ別

第7章世界のPOCT (ポイントオブケア検査) 市場の分析：適応症別

第8章世界のPOCT (ポイントオブケア検査) 市場の分析：技術別

第9章世界のPOCT (ポイントオブケア検査) 市場の分析：サンプルタイプ別

第10章世界のPOCT (ポイントオブケア検査) 市場の分析：購入形態別

第11章世界のPOCT (ポイントオブケア検査) 市場の分析：エンドユーザー別

第12章世界のPOCT (ポイントオブケア検査) 市場の分析：流通チャネル別

第13章世界のPOCT (ポイントオブケア検査) 市場の分析：地域別

第14章北米のPOCT (ポイントオブケア検査) 市場の分析

第15章欧州のPOCT (ポイントオブケア検査) 市場の分析

第16章アジア太平洋のPOCT (ポイントオブケア検査) 市場の分析

第17章中東・アフリカのPOCT (ポイントオブケア検査) 市場の分析

第18章南米のPOCT (ポイントオブケア検査) 市場の分析

第19章企業プロファイル

第20章付録